<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488408</url>
  </required_header>
  <id_info>
    <org_study_id>BGBC003</org_study_id>
    <nct_id>NCT02488408</nct_id>
  </id_info>
  <brief_title>A Phase Ib/II Multicenter Open-label Study of BGB324 in Patients With AML or MDS</brief_title>
  <official_title>A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BerGenBio ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BerGenBio ASA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ib/II multicentre open label study of BGb324 as a single agent in patients with AML
      or MDS or in a combination with cytarabine and decitabine in AML patients.

      BGB324 is a potent selective small molecule inhibitor of Axl, a surface membrane protein
      kinase receptor which is overexpressed in up to half of AML cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a dose-escalation of BGB324, an Axl kinase inhibitor, in patients with acute
      myeloid leukemia (AML) and myelodysplastic syndrome (MDS), followed by a cohort expansion
      study of BGB324 either as a single agent in patients with AML or MDS, or in combination with
      cytarabine (cytosine arabinoside, Ara-C) or decitabine in patients with AML.

      The study will run in Germany, Norway and the US and may enrol up to approximately 75
      patients with AML or MDS.

      The study consists of a dose-escalation phase to determine the MTD and/or recommended dose
      for Phase II (RP2D) of BGB324 in patients with relapsed or refractory AML or MDS (Part A)
      followed by a cohort expansion phase in up to four disease-specific cohorts (Part B).

      BGB324 will be administered orally according to a daily schedule, with the first three doses
      of Cycle 1 serving as a 'loading' dose. Each 21-day (three week) period will constitute 1
      cycle of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BGB324</measure>
    <time_frame>15 Months</time_frame>
    <description>Dose confirmation for Phase II</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To identify the maximum tolerated dose (MTD) of BGB324 in patients with relapsed or refractory AML following treatment with cytotoxic chemotherapy or a targeted or biologic agent, or in patients with high risk MDS (Norway only).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To identify the safety and tolerability of BGB324:
as a single agent in patients with AML who are unsuitable for intensive chemotherapy
in a combination with cytarabine in patients with AML who are unsuitable for intensive chemotherapy
in a combination with decitabine in patients with AML who are unsuitable for intensive chemotherapy (US only)
as a single agent in patients with previously treated MDS (US Only) or in patients with high/intermediate (int-2) risk MDS (Norway Only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB324</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Low dose cytarabine will be administered with BGB324 at a dose selected dose from Part A of the study</description>
    <arm_group_label>Part B</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine will be administered with BGB324 at a dose selected dose from Part A of the study</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed written informed consent

          2. Histological, molecular or cytological confirmation of:

             Part A:

               -  AML (with the exception of AML M3), patients with relapsed or refractory AML
                  following treatment with cytotoxic chemotherapy or a targeted or biologic agent

               -  high risk group MDS, according to IPSS Risk Stratification (Norway Only)

             Part B:

               -  AML (with the exception of AML M3):

               -  AML unsuitable for intensive chemotherapy

               -  newly diagnosed AML unsuitable for intensive chemotherapy

               -  MDS:

               -  high/intermediate (int-2) risk group MDS, according to IPSS Risk Stratification
                  (Norway Only)

               -  patients with previously treated MDS (with the exception of deletion 5q MDS) (US
                  only)

          3. Age 18 years or older

          4. Female patients of childbearing potential must have a negative serum pregnancy test
             within 3 days prior to taking their first dose of BGB324. Male patients and female
             patients of reproductive potential must practice highly methods of contraception
             throughout the study and for â‰¥ 3 months after the last dose of BGB324.

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

        Exclusion Criteria:

          1. Patients who have a matched donor and are candidates for allogeneic bone marrow
             transplantation

          2. Pregnant or lactating

          3. Abnormal left ventricular ejection fraction (less than the lower limit of normal for a
             patient of that age at the treating institution or &lt;45%, whichever is lower).

          4. Congestive cardiac failure of &gt;Grade 2 severity according to the NYHA defined as
             symptomatic at less than ordinary levels of activity

          5. Unstable cardiac disease, including unstable angina or unstable hypertension, or need
             to change medication within 6 weeks of provision of consent due to lack of disease
             control

          6. Ischemic cardiac event including myocardial infarction within 3 months prior to first
             dose

          7. Current treatment with any agent known to cause Torsades de Pointes which cannot be
             discontinued at least five half-lives or two weeks prior to the first dose of study
             treatment.

          8. Treatment with any of the following; histamine receptor 2 inhibitors, proton pump
             inhibitors or antacids within 3 days or 5 half-lives of administration of BGB234,
             whichever is longer.

          9. Treatment with any medication which is predominantly metabolized by CYP3A4 and has a
             narrow therapeutic index.

         10. Radiotherapy or chemotherapy within the 14 days prior to the first dose of BGB324
             being administered (other than hydroxyurea)

         11. Active, uncontrolled central nervous system (CNS) disease including CNS leukemia

         12. Major surgery within 28 days prior to the start of BGB324 - excluding skin biopsies
             and procedures for insertion of central venous access devices

         13. Prior exposure to Astellas ASP2215.

         14. Unresolved CTCAE &gt;Grade 2 toxicity (other than stable toxicity) from previous
             anti-cancer therapy excluding alopecia.

        Full eligibility criteria available in the Protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonja Loges, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf Martinistrasse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Murray Yale, MD, PhD</last_name>
    <phone>+44 7557 818330</phone>
    <email>murray.yule@bergenbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonja Loges, MD, PhD</last_name>
    <phone>+49 407-410-51969</phone>
    <email>s.loges@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Parrott</last_name>
      <phone>319-353-6347</phone>
      <email>karen-parrott@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Carlos E Vigil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cancer Hospital &amp; Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Vittorio</last_name>
      <phone>614-293-7940</phone>
      <email>molly.vittorio@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>William Blum, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cora Cheung</last_name>
      <phone>713-792-3461</phone>
      <email>cmcheung@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jorge Cortes, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Frankfurt, Medizinische Klinik II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Hefermehl</last_name>
      <phone>+49 69 6301 86708</phone>
      <email>Laura.Hefermehl@kgu.de</email>
    </contact>
    <investigator>
      <last_name>JÃ¶rg Chromik, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf Martinistrasse</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja T Loges, MD, PhD</last_name>
      <phone>+49 407-410-51969</phone>
      <email>s.loges@uke.de</email>
    </contact>
    <investigator>
      <last_name>Sonja Loges, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Samson</last_name>
      <phone>+49 (511) 532 9321</phone>
      <email>samson.gabriele@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Michael Heuser, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Ulm, Oberer Eselsberg, Zentrum fÃ¼r Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Wetzel</last_name>
      <phone>+49 (0) 731 500 45709</phone>
      <email>manuela.wetzel@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Peter Paschka, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Emblem Lehmann</last_name>
      <phone>+47 59972890/ 95975516</phone>
      <email>marianne.emblem.lehmann@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>BjÃ¸rn Tore Gjertsen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bergenbio.com</url>
    <description>Please see BerGenBio's website for more information.</description>
  </link>
  <reference>
    <citation>Janning M, Ben-Batalla I, Loges S. Axl inhibition: a potential road to a novel acute myeloid leukemia therapy? Expert Rev Hematol. 2015 Apr;8(2):135-8. doi: 10.1586/17474086.2015.997704. Epub 2015 Jan 12.</citation>
    <PMID>25578023</PMID>
  </reference>
  <reference>
    <citation>Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013 Oct 3;122(14):2443-52. doi: 10.1182/blood-2013-03-491431. Epub 2013 Aug 27.</citation>
    <PMID>23982172</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

